HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-22. Numbers and descriptions here follow the published literature rather than marketing material.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Magnesium forms a variety of compounds important to industry and biology, including magnesium carbonate, magnesium chloride, magnesium citrate, magnesium hydroxide (milk of magnesia), magnesium oxide, magnesium sulfate, and magnesium sulfate heptahydrate (Epsom salts). As recently as 2020, magnesium hydride was under investigation as a way to store hydrogen.
=== Risk modifiers === Environmental factors such as infections, geographic latitude, birth weight, antibiotic use, intestinal microbiota, socioeconomic status, hygiene, breastfeeding, and the timing of introduction of gluten into an infant's diet are theorised to contribute to the development of coeliac disease in genetically predisposed individuals. The consumption of gluten and timing of introduction, in a baby's life does not appear to increase the risk of coeliac disease, however in those who are genetically predisposed to coeliac disease, large amounts of gluten early in life may increase the risk of developing coeliac disease.
=== CSIR India === In 2009, Ayyadurai was hired by India's Council of Scientific and Industrial Research (CSIR), India's largest science agency, by its director general, Samir K. Brahmachari. CSIR was mandated to create a new company, CSIR Tech, that would establish businesses using the research conducted by the country's many publicly owned laboratories. Ayyadurai reported that he had spent months trying to create a business plan for CSIR Tech, but received no response from Brahmachari. Ayyadurai then distributed a draft plan, which was not authorized by CSIR, to the agency's scientists that requested feedback and criticized management. His job offer was subsequently withdrawn five months after the position was offered. Brahmachari said that "the offer was withdrawn as [Ayyadurai] did not accept the terms and conditions and demanded unreasonable compensation." In its report, The New York Times said that "going public with such accusations is highly unusual. Mr. Ayyadurai circulated his paper not just to the agency's scientists but to journalists, and wrote about his situation to Prime Minister Manmohan Singh." In that letter, Ayyadurai said his report was intended to explore institutional barriers to CSIR's entrepreneurial mandate. He said that CSIR scientists reported that "they work in a medieval, feudal environment" that required a "major overhaul". The letter was co-authored by a colleague, Deepak Sardana.
High amounts of vapor particle deposition are believed to enter into the lungs with each puff because the particle size in e-cigarette vapors is within the respiratory range. After a puff, the inhaled vapor changes in the size distributions of particles in the lungs. This results in smaller exhaled particles. E-cigarette vapor is made up of fine and ultrafine particles of particulate matter. Vaping generates particulate matter 2.5 μm or less in diameter (PM2.5), but at notably less concentrations compared to cigarette smoke. Particle concentrations from vaping ranged from 6.6 to 85.0 μg/m3. Particle-size distributions of particulate matter from vaping differ across studies. The longer the puff duration the greater the amount of particles produced. The greater the amount of nicotine in the e-liquid the greater the amount of particles produced. Flavoring does not influence the particle emissions. The various kinds of devices such as cig-a-likes, medium-sized vaporizers, tanks, or mods may function at different voltages and temperatures. Thus, the particle size of the e-cigarette vapor can vary, due to the device used. Comparable to cigarette smoke, the particle size distribution mode of e-cigarette vapor ranged from 120 to 165 nm, with some vaping devices producing more particles than cigarette smoke.
Sources: en.wikipedia.org
The result was twelve protein-like amino acids: aspartic acid, glutamic acid, glycine, alanine, valine, leucine, isoleucine, serine, threonine, proline, tyrosine, and phenylalanine. Many other similar experiments were carried out by teams of scientists such as Heyns and Pavel, Oro and Kamat, and Fox and Windsor that led to the production of amino acids.
== Sample preparation == For most clinical methods using ICP-MS, there is a relatively simple and quick sample prep process. The main component to the sample is an internal standard, which also serves as the diluent. This internal standard consists primarily of deionized water, with nitric or hydrochloric acid and indium and/or gallium. The addition of volatile acids allows for the sample to decompose into its gaseous components in the plasma which minimizes the ability for concentrated salts and solvent loads to clog the cones and contaminate the instrument. Depending on the sample type, usually 5 mL of the internal standard is added to a test tube along with 10–500 microliters of sample. This mixture is then vortexed for several seconds or until mixed well and then loaded onto the autosampler tray. For other applications that may involve very viscous samples or samples that have particulate matter, a process known as sample digestion may have to be carried out before it can be pipetted and analyzed. This adds an extra first step to the above process and therefore makes the sample prep more lengthy.
This species is of typical elongated tetra appearance; it is of plain basic coloration, but with two distinct, adjacent, longitudinal stripes, white above black. The eye has two thin but distinctive color bands across the top, red above yellow. It grows to a maximum overall length of approximately 4 cm (1.6 in). Befitting its common name, it slightly resembles the neon tetra, which belongs to a different genus (Paracheirodon). Females are often larger than males. The variety named Diamond or Brilliant does not have a white stripe but instead displays more reflective scales around the head. The fish's natural diet consists of small invertebrates and plants. H. herbertaxelrodi is commonly kept as an aquarium fish by hobbyists. The black neon tetra is sometimes called the black tetra, but that name more properly refers to a different species, Gymnocorymbus ternetzi.
Sources: en.wikipedia.org
A time-dependent recoverable component – this causes the development of microcracks, which can lead to fracturing and, ultimately, a breakthrough; A time-dependent irrecoverable component – this is commonly referred to as creep, which is related with the mechanisms responsible for glacier flow (long term) and plays a negligible role in the response of an ice road to loading. Thus, an ice cover may be able to safely support a vehicle, but if it remains on the ice for too long, deformation will continue via microcracking, leading to the collapse of the ice cover below the vehicle. Recommendations vary as to how this can be avoided. Some sources prescribe a maximum of two hours for a stationary load, which is also what Gold recommended. Others advise to use the freeboard of the ice as an indicator, which can be done by drilling a hole in it and monitoring the distance between the water in the hole and the ice surface. The vehicle should be removed before the water reaches the surface in that hole. Another reason why the amount of freeboard matters is that if the water makes its way onto the ice surface (through cracks and fissures), the ice cover's bearing capacity diminishes rapidly, which can accelerate breakthrough. For long-term loads, a professional engineer may have to be consulted.
== Diseases == Gonadotropin deficiency due to pituitary disease results in hypogonadism, which can lead to infertility. Treatment includes administered gonadotropins, which, therefore, work as fertility medication. Such can either be produced by extraction and purification from urine or be produced by recombinant DNA. Failure or loss of the gonads usually results in elevated levels of LH and FSH in the blood. LH insensitivity, which results in Leydig cell hypoplasia in males, and FSH insensitivity, are conditions of insensitivity to LH and FSH, respectively, caused by loss-of-function mutations in their respective signaling receptors. Another closely related condition to these is GnRH insensitivity.
=== Acquisition by Valeant Pharmaceuticals === In August 2015, Valeant Pharmaceuticals and Sprout Pharmaceuticals announced that Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.